PST 2238 as an antihypertensive compound that antagonizes the effect of endogenous cardiac glycosides.
This review examines the role of endogenous cardiac glycosides (OLF--ouabain like factors) in the pathogenesis of hypertension. The discovery of ouabain as a new adrenal hormone affecting salt and water homeostasis has initiated research on a new group of compounds. OLF may provide new insights into the mechanisms and therapy of common cardiovascular diseases. PST 2238 (17beta-(3-furyl)-5beta-androstane-3beta-14beta-17alpha-triol), an antagonist of endogenous ouabain, might open new possibilities for the therapy of hypertension and congestive heart failure.
Winnicka
Katarzyna
K
Department of Drug Technology, Medical University of Białystok, 1 Kilińskiego Str., 15-089 Białystok, Poland.
Tomasiak
Marian
M
D000732:Androstanols / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002301:Cardiac Glycosides / Q000037:antagonists & inhibitors*; D006801:Humans; D006973:Hypertension / Q000503:physiopathology; D010042:Ouabain / Q000037:antagonists & inhibitors
D000732:Androstanols; D000959:Antihypertensive Agents; D002301:Cardiac Glycosides; D010042:Ouabain; C106263:rostafuroxin